

Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) A method of diagnosing an aggressive form of cancer, the method comprising steps of:

providing a genetic sample from a test sample of a tumor;

analyzing expression of Wnt5a and at least one gene ~~a set of genes~~ selected from the group consisting of ~~Wnt5a~~, MART-1, pirin, HADHB, CD63, ENDRB, PGAM1, HXB, RXRA, integrin b1, syndecan 4, tropomyosin 1, AXL, EphA2, GAP43, PFKL, synuclein a, annexin A2, CD20, and RAB2; and

identifying the tumor as aggressive or non-aggressive based on the expression pattern of the genes.

2. (Original) The method of claim 1, the method further comprising step of:
selecting a treatment regimen for an individual with the tumor based on whether the tumor is aggressive or non-aggressive.

3. (Original) The method of claim 1, wherein the cancer is malignant melanoma.

4. (Currently amended) A method of diagnosing an aggressive form of malignant melanoma, the method comprising steps of:

providing a genetic sample from a test sample of a tumor;

determining expression of *Wnt5a*; and

identifying the tumor as aggressive or non-aggressive based on the expression of *Wnt5a*;
and

selecting a treatment regimen for an individual with the tumor based on whether the tumor is aggressive or non-aggressive.

5. (Canceled)

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Canceled)

10. (Canceled)

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Canceled)

21. (Withdrawn) A method of diagnosing an aggressive form of cancer, the method comprising steps of:

providing a genetic sample from a test sample of a tumor;

analyzing expression of Wnt5a gene;

analyzing expression of at least one gene selected from the group consisting of MART-1, pirin, HADHB, CD63, ENDRB, RGAM1, HXB, RXRA, integrin b1, syndecan 4, tropomyosin 1, AXL, EphA2, GAP43, PFKL, synuclein a, annexin A2, CD20, and RAB2; and

identifying the tumor as aggressive or non-aggressive based on the expression pattern of the genes.

22. (Withdrawn) The method of claim 21, wherein the step of analyzing expression of at least one gene comprises analyzing expression of at least two genes selected from the group consisting of MART-1, pirin, HADHB, CD63, ENDRB, PGAM1, HXB, RXRA, integrin b1, syndecan 4, tropomyosin 1, AXL, EphA2, GAP43, PFKL, synuclein a, annexin A2, CD20, and RAB2.

23. (Withdrawn) The method of claim 21, wherein the step of analyzing expression of at least one gene comprises analyzing expression of at least three genes selected from the group consisting of MART-1, pirin, HADHB, CD63, ENDRB, PGAM1, HXB, RXRA, integrin b1, syndecan 4, tropomyosin 1, AXL, EphA2, GAP43, PFKL, synuclein a, annexin A2, CD20, and RAB2.

24. (Withdrawn) The method of claim 1, wherein the step of analyzing comprises analyzing expression of Wnt5a, MART-1, pirin, HADHB, CD63, ENDRB, PGAM1, HXB, RXRA, integrin b1, syndecan 4, tropomyosin 1, AXL, EphA2, GAP43, PFKL, synuclein a, annexin A2, CD20, and RAB2.

25. (New) The method of claim 4, wherein the cancer is malignant melanoma.